eurodegenerative Changes in Alzheimer’s Disease: Identifying potential effects of Victoza® on degenerative changes

Dept. of Pharmacology0 个研究点开始时间: 2011年6月1日最近更新: 2016年9月19日

适应症

试验速览

暂无简介。

•Patients diagnosed with AD by MMSE score and/or spinal puncture (If MMSE score is between 18-21 the patient is diagnosed by clinical symptoms only. If the MMSE score is > 22 a spinal puncture will be performed to diagnose the patient)
•Age = 50 years and = 80 years
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•Diabetes mellitus
•Liver or kidney insufficiency (alanine transferase levels more tha twice upper normal, plasma creatinine > 130µmol/l), clinical relevant anaemia
•Current or earlier presence of another CNS disease (except for well-treated depression) or clinical relevant liver disease, kidney disease or endocrinological disease (except hypothyreoism).
•Current or history of chronic or acute pancreatitis
•If patients are treated with SSRI or SSRI similar drugs or antihypertensives this treatment should be stable
•Claustrophobia or other missing co-orporation
•Severe overweight > 130kg
•Ferro-magnetic prosthesis, pacemaker or other metals incorporated in the body
•Significant abnormities in the brain detected by MR scanning
•Known abuse of alcohol or drugs
•Every disease or treatment that the head investigator considers to have a possible effect on results of the study
•Allergy to the drugs or diagnosing procedure used in the study
•Participation in a clinical study 3 months prior to inclusion in this study
•Patients who have previously participated in investigations with isotopes or ionizing radiation

发起方

Dept. of Pharmacology